Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-348(5)Drug: CKD-828, D097, D337
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 65
- Registration Number
- NCT05749861
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378
Phase 1
Completed
- Conditions
- Type II Diabetes
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT05741437
- Locations
- 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of
Pharmacokinetics and Safety/Tolerability of CKD-379
Phase 1
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- Drug: CKD-379Drug: D759+D745+D150
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT05719155
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-386(5)Drug: D013, D326, D337
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 63
- Registration Number
- NCT05698043
- Locations
- 🇰🇷
H plus Yangji hospital, Seoul, Korea, Republic of
A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia
Phase 2
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: CKD-498 dose#2Drug: CKD-498 dose#3Drug: CKD-498 dose#1Drug: Placebo of CKD-498 dose#1Drug: Placebo of CKD-498 dose#3Drug: Placebo of CKD-498 dose#2
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 121
- Registration Number
- NCT05677438
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting Condition
Phase 1
Completed
- Conditions
- Endocrine, Nutritional and Metabolic Diseases
- Interventions
- Drug: CKD-387Drug: D484
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT05673369
- Locations
- 🇰🇷
Bumin Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia
Phase 3
Recruiting
- Conditions
- Primary Hypercholesterolemia
- Interventions
- Drug: D086Drug: D377Drug: Placebo (for CKD-331)Drug: CKD-331Drug: Placebo (for D377)Drug: Placebo (for D086)
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 228
- Registration Number
- NCT05657574
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391
Phase 1
Completed
- Conditions
- Dyslipidemias
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 69
- Registration Number
- NCT05634447
- Locations
- 🇰🇷
Bumin Hospital(Seoul), Seoul, Gangseo-gu, Korea, Republic of
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
Phase 1
Completed
- Conditions
- Alopecia
- Interventions
- Drug: CKD-843 A 45mg(Multiple dose)Drug: CKD-843 A 45mgDrug: CKD-843 A 55mg(Multiple dose)Drug: CKD-843 A 55mgDrug: CKD-843-R
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 41
- Registration Number
- NCT05587699
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-341 in Healthy Subjects
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: CKD-341
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT05571813
- Locations
- 🇰🇷
Central Hospital, Gyeonggi-do, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath